Cordant Inc’s Prime Medicine PRME Stock Holding History

Cordant Inc’s Portfolio PRME Stock Details PRME Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-33	Closed	-$66	–	96
2025 Q1	$66	Buy	+33	New	+$84	﹤0.01%	108

Other funds holding PRME

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Cordant Inc's PRME Position: Q2 2025 in Review

Cordant Inc sold out of Prime Medicine (PRME) in Q2 2025, closing a stake of 33 shares — an estimated $66 sold.

Cordant Inc first reported a position in PRME in Q1 2025 and held it in 1 quarter. The position peaked at $66 in Q1 2025. 121 funds tracked by Wall St. Rank hold PRME as of Q2 2025.

Cordant Inc reported no remaining Prime Medicine position as of Q2 2025 after selling out during the quarter.
Cordant Inc sold 33 Prime Medicine shares in Q2 2025, an estimated $66.
Cordant Inc first reported a position in Prime Medicine in Q1 2025 and held it in 1 quarter.
Cordant Inc's Prime Medicine position peaked at $66 in Q1 2025.
121 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2025.

Based on Cordant Inc's 13F filing for Q2 2025, filed 15 Jul 2025.